Is AbbVie Stock a Buy Now?
Pharmaceutical giant (NYSE: ABBV) is getting used to life without Humira. Not literally, but the former global top-seller did lose patent exclusivity last year, and sales plummeted as cheaper generic alternatives entered the market.
So, why has AbbVie stock soared nearly 30% over the past three months to new all-time highs? More importantly, have investors missed their opportunity to buy the stock and still see satisfactory investment returns?
AbbVie's management has put on a masterclass in executing its transition away from a patent-protected Humira, and it makes the stock a compelling long-term investment idea.
Source Fool.com
AbbVie Inc. Stock
€152.18
1.590%
With 21 Buy predictions and not a single Sell prediction AbbVie Inc. is an absolute favorite of our community.
With a target price of 174 € there is a slightly positive potential of 14.34% for AbbVie Inc. compared to the current price of 152.18 €.
